Florian Marks, Vera von Kalckreuth, Peter Aaby, Yaw Adu‐Sarkodie et al.
BACKGROUND: Available incidence data for invasive salmonella disease in sub-Saharan Africa are scarce. Standardised, multicountry data are required to better understand the nature and burden of disease in Africa. We aimed to measure the adjusted incidence estimates of typhoid fever and invasive non-...
Robert J. Commons, J. A. Simpson, Kamala Thriemer, Georgina Humphreys et al.
BACKGROUND: Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports of treatment failure. We did a systematic review and meta-analysis to investigate the effect of chloroquine dose and the addition of primaquine on the risk of recurrent vivax malaria acr...
Kamala Thriemer, Albino Bobogare, Benedikt Ley, Clarice Samo Gudo et al.
The goal to eliminate malaria from the Asia-Pacific by 2030 will require the safe and widespread delivery of effective radical cure of malaria. In October 2017, the Asia Pacific Malaria Elimination Network Vivax Working Group met to discuss the impediments to primaquine (PQ) radical cure, how these ...
Mohammad Shafiul Alam, Mohammad Golam Kibria, Nusrat Jahan, Kamala Thriemer et al.
BACKGROUND: Glucose-6-Phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy worldwide, no reliable bedside diagnostic tests to quantify G6PD activity exist. This study evaluated two novel quantitative G6PD diagnostics. METHODS: Participants with known G6PD activity were enrolled i...
Kamala Thriemer, Benedikt Ley, Albino Bobogare, Dysoley Lek et al.
The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest challenges for achieving malaria elimination from the Asia-Pacific by 2030. During the annual meeting of the Asia Pacific Malaria Elimination Network Vivax Working Group in October 2016, a round table discuss...
Benedikt Ley, Nick Luter, Fe Esperanza Espino, Angela Devine et al.
The only currently available drug that effectively removes malaria hypnozoites from the human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side effects in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. Recently a number of qualitative and a quantitative...
Daniel Pfeffer, Benedikt Ley, Rosalind E. Howes, Patrick Adu et al.
BACKGROUND: The radical cure of Plasmodium vivax and P. ovale requires treatment with primaquine or tafenoquine to clear dormant liver stages. Either drug can induce haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, necessitating screening. The reference diagnostic ...
Robert J. Commons, J. A. Simpson, Kamala Thriemer, Mohammad Hossain et al.
BACKGROUND: A 14-day course of primaquine is used for radical cure of Plasmodium vivax and Plasmodium ovale malaria only. We quantified the risk of P vivax parasitaemia after treatment of Plasmodium falciparum with commonly used antimalarial drugs to assess the potential benefits of radical cure for...
Benedikt Ley, Mohammad Shafiul Alam, James J. O’Donnell, Mohammad Hossain et al.
BACKGROUND: Glucose-6-phosphate-dehydrogenase-deficiency (G6PDd) is a major risk factor for primaquine-induced haemolysis. There is a need for improved point-of-care and laboratory-based G6PD diagnostics to unsure safe use of primaquine. METHODS: G6PD activities of participants in a cross-sectional ...
Peter Starzengrüber, Hans‐Peter Fuehrer, Benedikt Ley, Kamala Thriemer et al.
BACKGROUND: The WHO has reported that RDT and microscopy-confirmed malaria cases have declined in recent years. However, it is still unclear if this reflects a real decrease in incidence in Bangladesh, as particularly the hilly and forested areas of the Chittagong Hill Tract (CHT) Districts report m...
Mohammad Hossain, Robert J. Commons, Nicola Davies, Kamala Thriemer et al.
BACKGROUND: There is a high risk of Plasmodium vivax parasitaemia following treatment of falciparum malaria. Our study aimed to quantify this risk and the associated determinants using an individual patient data meta-analysis in order to identify populations in which a policy of universal radical cu...
Hans‐Peter Fuehrer, Peter Starzengrüber, Paul Swoboda, Wasif Ali Khan et al.
In spite of the high prevalence of malaria in Southeastern Bangladesh, there remains a significant shortage of information regarding the presence of three of five human malaria parasites: Plasmodium ovale, P. malariae, and P. knowlesi. The presence of P. ovale and P. knowlesi has previously never be...
Robert J. Commons, J. A. Simpson, Kamala Thriemer, Cindy S. Chu et al.
BACKGROUND: Malaria causes a reduction in haemoglobin that is compounded by primaquine, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The aim of this study was to determine the relative contributions to red cell loss of malaria and primaquine in patients with unc...
MalariaGEN, Ishag Adam, Mohammad Shafiul Alam, Sisay Getachew Alemu et al.
<ns3:p> This report describes the MalariaGEN Pv4 dataset, a new release of curated genome variation data on 1,895 samples of <ns3:italic>Plasmodium vivax</ns3:italic> collected at 88 worldwide locations between 2001 and 2017. It includes 1,370 new samples contributed by MalariaGEN and VivaxGEN partn...
Benedikt Ley, Mohammad Shafiul Alam, Kamala Thriemer, Mohammad Hossain et al.
BACKGROUND: The Bangladeshi national treatment guidelines for uncomplicated malaria follow WHO recommendations but without G6PD testing prior to primaquine administration. A prospective observational study was conducted to assess the efficacy of the current antimalarial policy. METHODS: Patients wit...